,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu']
fascinating discussions ongoing in #breastcancer oncology circles on reliability of her-2 evaluation by #pathologists following #asco22 enhertu data in low her-2 cancers. members of my tribe - are you ready to draw the line in the sand between true her-2 zero &amp; everything else?
Pancreatic cancer researcher and GI pathologist. Striving to improve the lives of patients with cancer.